Long-term efficacy data for Pfizer Inc.’s Elrexfio (elranatamab-bcmm) strengthens the bispecific antibody's position in the increasingly competitive space of BCMA-directed therapies for multiple myeloma. But apart from efficacy data, what may ultimately differentiate the growing number of BCMA-targeting therapies is how convenient they are to receive for patients.
Pfizer's Elrexfio Shows Long-Term OS, But Convenience Counts Too
The drug maker presented data from the pivotal Phase II trial at EHA showing median OS of more than two years for Elrexfio.
